- Anavex Life Sciences (AVXL, Financial) appoints Dr. Audrey Gabelle to its Scientific Advisory Board.
- Dr. Gabelle brings expertise in Alzheimer's disease, digital health, and AI to support the development of blarcamesine (ANAVEX®2-73).
- The appointment aims to advance Anavex's innovative Alzheimer’s treatments.
New York, April 23, 2025 – Anavex Life Sciences (AVXL), a clinical-stage biopharmaceutical company, has announced the appointment of Professor Dr. Audrey Gabelle, MD, PhD, to its Scientific Advisory Board. Dr. Gabelle, an esteemed specialist in predictive, personalized medicine and digital health, will provide her expertise to support the development of blarcamesine (ANAVEX®2-73), a promising oral treatment for Alzheimer's disease.
Dr. Gabelle’s distinguished career includes more than 10 years of experience in clinical Phase I-IV trials, managing over 400 memory centers within the French network, and authoring over 200 scientific papers. Her work in establishing the NeuroCognition biobank, comprising more than 35,000 samples, highlights her expertise in Alzheimer's diagnosis and biomarkers. Additionally, Dr. Gabelle's recent focus on real-world evidence and digital health strategies, honed through training at Columbia and Harvard Universities, aligns with Anavex's goals for innovative therapeutic developments.
Christopher U Missling, PhD, President and CEO of Anavex, expressed enthusiasm about Dr. Gabelle’s appointment, noting her broad expertise in Alzheimer's disease and digital health as critical to advancing blarcamesine. Anavex aims to leverage her knowledge to enhance its efforts in delivering cutting-edge treatments that address the global unmet medical needs caused by Alzheimer’s disease.
